Withdrawn laboratory study identifies gene expression changes in valvular heart disease-associated atrial fibrillation

This is a withdrawn laboratory study that conducted RNA sequencing on peripheral blood mononuclear cells (PBMCs) from 15 patients with valvular heart disease-associated atrial fibrillation (VHD-AF) and 15 age- and sex-matched healthy controls. The analysis identified 3,308 differentially expressed genes, with 2,891 upregulated and 417 downregulated, and found significant enrichment in pathways such as cytokine-cytokine receptor interaction (P=1.2e-15), TNF signaling (P=3.4e-08), and nucleosome assembly (P=8.9e-12). The authors propose that these molecular signatures could inform the development of targeted therapies, including TNF inhibition and histone-modifying agents, and serve as minimally invasive biomarkers for VHD-AF.

The study acknowledges limitations, noting that the molecular drivers distinguishing VHD-AF from other atrial fibrillation etiologies remain poorly defined. The withdrawn status indicates that the evidence may be incomplete or uncertain, and the small sample size of 15 patients per group limits generalizability. No safety data, adverse events, or follow-up duration were reported, and funding or conflicts of interest details are not provided.

In terms of practice relevance, the findings are exploratory and highlight potential avenues for future research rather than immediate clinical application. The authors cautiously suggest that TNF inhibition and histone-modifying agents could be therapeutic strategies, and PBMC-derived signatures might offer biomarkers for this specific population. However, these proposals are speculative and require rigorous validation in larger, prospective studies before any clinical implications can be considered.